Seagen Inc

Seagen — Merger or Acquisition (March 2023)

20 slides from Seagen's merger presentation, Mar 13, 2023

  1. Slide 1: Pfizer Invests $43B to Battle Cancer

    Exhibit 99.2 Pfizer Invests $43B to Battle Cancer March 13, 2023 Breakthroughs that change patients’ lives 1

  2. Slide 2: Forward Looking Statements and Other Notices

    Forward Looking Statements and Other Notices Our discussions during this conference call will include forward-looking information about, among other topics, Pfizer’s proposed acquisition of Seagen, Pfizer’s and Seagen’s commercialized and pipeline products, including anticipated launches thereof, an

  3. Slide 3: Additional Information and Non-Solicitation

    Additional Information and Non-Solicitation Additional Information and Where to Find It In connection with the proposed transaction, Seagen will be filing documents with the SEC, including preliminary and definitive proxy statements relating to the proposed transaction. The definitive proxy statemen

  4. Slide 4: Today's Speakers

    Today’s Speakers Dr. Albert Bourla David Denton Chris Boshoff David Epstein Chairman and Executive Vice President, Chief Development Officer, Chief Executive Officer, Chief Executive Officer, Chief Financial Officer, Oncology & Rare Disease, Seagen Pfizer Pfizer Pfizer 4

  5. Slide 5: Strategic Rationale: Great News for Pfizer, Seagen & Patients with Cancer

    Strategic Rationale Great News for Pfizer, Seagen & Patients with Cancer Combination of Pfizer and Seagen will have the potential to: • Enhance Pfizer’s position as a leading company in the important oncology space • Replicate Pfizer’s COVID-19 success in cancer • Help bring Seagen’s proven and prom

  6. Slide 6: Strategic Rationale: What Seagen Brings to Pfizer

    Strategic Rationale What Seagen Brings to Pfizer Portfolio Pipeline & Platform People • Four cancer treatments in • 11 clinical programs, many • Smart, dedicated and purpose- the market with large potential patient driven team populations • Three ADCs • Expertise and insights will • Potential breakt

  7. Slide 7: Strategic Rationale: Potential Growth Accelerants

    Strategic Rationale Potential Growth Accelerants + Commercial R&D • Speed via enhanced site • Combined U.S. infrastructure network 3x that of Seagen alone • Combo opportunities for • Deeper and broader compelling therapeutic capabilities regimens • Global footprint • Complementary capabilities 7

  8. Slide 8: Antibody-Drug Conjugates: Emerging Pillar of Cancer Care

    Immunotherapy Precision Therapy Antibody-Drug Conjugates Radio- & Chemotherapy Surgery Seagen Platform, Portfolio & Fit with Pfizer Antibody-Drug Conjugates: Emerging Pillar of Cancer Care Seagen at the Forefront of Shifting Therapeutic Paradigm Towards Targeted Cytotoxic Agents Seagen is the Leader

  9. Slide 9: Seagen In-Line Portfolio Across a Range of Tumor Types

    Seagen Platform, Portfolio & Fit with Pfizer Seagen In-Line Portfolio Across a Range of Tumor Types 4 Approved Products with Active Lifecycles Best-in-Class TKI for Foundation of care and First- First-in-Class ADC for Locally HER2+ Breast Cancer and First First-in-Class ADC for Overview in-Class ADC

  10. Slide 10: Pfizer & Seagen: Enhanced Leadership Position in Oncology

    Seagen Platform, Portfolio & Fit with Pfizer Pfizer & Seagen: Enhanced Leadership Position in Oncology (1) Complementary Portfolios Across In-Line Medicines & Late-Stage Development Programs Precision Medicine Breast Cancer Genitourinary Cancer Hematology (Colorectal, Melanoma and Lung) + KAT6i Tala

  11. Slide 11: Breakthrough Potential with 15 Clinical Assets in Phase 1/2

    Seagen Platform, Portfolio & Fit with Pfizer Breakthrough Potential with 15 Clinical Assets in Phase 1/2 Pipeline of Early-Stage NMEs Have Potential to Drive Significant Long-Term Growth (1) (1) TIVDAK + Carboplatin, Phase 1/2 SGN-B6A - Phase 1 Disitamab Vedotin (DV) - Phase 2 First ADC targeting Ti

  12. Slide 12: Pfizer & Seagen: Combining Expertise to Create Potentially More Value

    Seagen Platform, Portfolio & Fit with Pfizer Pfizer & Seagen: Combining Expertise to Create Potentially More Value Significant Potential Upside by Combining Pfizer & Seagen Oncology Capabilities Leveraging Pfizer protein engineering capability Incorporating Pfizer’s small molecule degrader to advanc

  13. Slide 13: Transaction Overview

    Transaction Overview & 2030 Contribution Transaction Overview • $229 per share; 100% cash consideration Purchase • Transaction value of approximately $43 billion (inclusive of net debt) Price • Premium of 33% to the 3/10/23 closing price and 42% premium to the unaffected closing price on 2/24/23 (3)

  14. Slide 14: Strengthens Pfizer's Long-Term Growth Plans

    Transaction Overview & 2030 Contribution Illustrative* Strengthens Pfizer's Long-Term Growth Plans Seagen expects to generate revenue of more than $2B in 2023. Pfizer believes Seagen could contribute more than $10B to 2030 risk adjusted revenues, subject to clinical and regulatory success ~$84B 5 4

  15. Slide 15: Path to $25B Potential Revenue in 2030 from New Business Development

    Transaction Overview & 2030 Contribution Illustrative* (1) Path to $25B Potential Revenue in 2030 from New Business Development Remaining Gap <$5B ~$84B 5 4 $XB ~$25B '25-'30 CAGR 10% 1 ~$52B Seagen >$10.0B ~$70B '22-'25 CAGR 6% '25-'30 CAGR 6% 3 with new launches ~$20B 2 ~$17B New launches Complete

  16. Slide 16: Key Takeaways

    Key Takeaways Key Takeaways ü Deploying Pfizer's financial resources to advance the battle against cancer, a leading cause of death worldwide with a significant impact on public health ü Accelerating the next-generation of cancer treatments through the combination of Seagen's ADC technology with the

  17. Slide 17: Q&A Session

    Q&A Session Breakthroughs that change patients’ lives 17

  18. Slide 18: Footnotes: Definitions of Acronyms

    Footnotes (Page 1 of 3) Definitions of Acronyms: • ADC: Antibody-drug conjugate • mBC: Metastatic Breast Cancer • AML: Acute Myeloid Leukemia • mCC: Metastatic Cervical Cancer • BD: Business Development • MDS: Myelodysplastic Syndrome • B7H4: B7 Homolog 4 • mTNBC: Metastatic Triple Negative Breast C

  19. Slide 19: Footnotes: Seagen Commercialization Territories

    Footnotes (Page 2 of 3) (1) Seagen selected commercialization territories: ® • Adcetris (brentuximab vedotin) – U.S. & Canada (collaboration with Takeda) ® • Padcev (enfortumab vedotin) – U.S. (co-commercialization with Astellas), Canada and Latin America (the latter through distributor Adium). Seag

  20. Slide 20: Footnotes: Adjusted Income and Adjusted Diluted EPS Definitions

    Footnotes (Page 3 of 3) (3) Adjusted income and Adjusted diluted EPS are defined as U.S. GAAP net income attributable to Pfizer Inc. shareholders and Reported diluted EPS attributable to Pfizer Inc. common shareholders before the impact of amortization of intangible assets, certain acquisition-relat

Seagen — Merger or Acquisition (March 2023) on 6ix